Comparative Pharmacology
Head-to-head clinical analysis: CAPRELSA versus SORAFENIB TOSYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPRELSA versus SORAFENIB TOSYLATE.
CAPRELSA vs SORAFENIB TOSYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and oncogenesis, including VEGFR2, EGFR, and RET.
Sorafenib is a multikinase inhibitor that inhibits Raf serine/threonine kinases (C-Raf, B-Raf, and mutant B-Raf), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptor (PDGFR-β), and other kinases, thereby inhibiting tumor cell proliferation and angiogenesis.
300 mg orally once daily, with or without food.
400 mg orally twice daily on an empty stomach (at least 1 hour before or 2 hours after a meal).
None Documented
None Documented
Terminal half-life approximately 90 hours (range 30–150 hours), supporting once-daily dosing; steady-state achieved by day 15.
Terminal half-life of sorafenib is approximately 25-48 hours (mean ~37 hours); clinical steady-state achieved within 7 days.
Primarily fecal (approximately 75% of administered dose, mainly as unchanged drug and metabolites); renal excretion accounts for about 25% (less than 1% unchanged).
Fecal (77%) as unchanged drug and metabolites; renal (19%) as glucuronide conjugates; <1% excreted unchanged in urine.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor